查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2010932

肺癌治療市場：2026-2032年全球市場預測（依治療分類、癌症類型、分子類型、給藥途徑、最終用戶和分銷管道分類）

Lung Cancer Drugs Market by Therapeutic Class, Cancer Type, Molecule Type, Route Of Administration, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，肺癌治療市場價值將達到 295.3 億美元，到 2026 年將成長至 320.7 億美元，到 2032 年將達到 550.7 億美元，複合年成長率為 9.31%。

主要市場統計數據
基準年 2025 295.3億美元
預計年份：2026年 320.7億美元
預測年份 2032 550.7億美元
複合年成長率 (%) 9.31%

本書權威地說明了分子科學、免疫腫瘤學的進步以及醫療保健服務的變化如何重塑肺癌治療策略和優先事項。

在分子科學、不斷發展的臨床範式和不斷變化的醫療服務模式的推動下，肺癌治療模式正在發生翻天覆地的變化。近年來，我們見證了治療治療方法從標準化的細胞毒性療法轉向利用腫瘤生物學特性、免疫調節和精準標靶治療。在此背景下，臨床醫生、保險公司和研發人員在治療方案選擇、聯合治療和患者篩選方面面臨新的挑戰，而這些都依賴先進的診斷技術和基於生物標記的患者登記。

免疫腫瘤學、精準標標靶治療、門診治療和不斷發展的診斷技術的發展趨勢如何全面改變腫瘤學的臨床路徑和商業策略。

科學突破已為肺癌的診斷、治療和管理帶來了變革性的變化，並惠及所有醫療機構。針對CTLA-4、PD-1和PD-L1路徑的免疫療法已從小眾適應症發展成為許多患者的基礎治療方法，而針對ALK、EGFR和ROS1突變的標靶治療也已成為分子分型患者群體的第一線治療策略。同時，將免疫調節劑與化療或標靶治療相結合的聯合治療模式正在重新定義療效預期和毒性管理。

近期美國貿易關稅對跨境供應鏈、臨床物流、價格壓力以及腫瘤領域的策略性生產選擇所產生的累積影響。

美國將於2025年開始實施累積關稅，這對全球肺癌治療藥物的供應鏈、籌資策略和定價產生了連鎖反應。依賴跨境供應活性成分、生物製藥製劑或成品的製造商面臨更高的接收成本，這迫使他們重新與供應商談判合約、進行區域採購或重新分配產能。因此，採購團隊和契約製造製造商不得不重新評估其供應商多元化和庫存策略，以減輕這種衝擊。

將治療領域、癌症類型、分子類別、給藥途徑和通路與商業和臨床策略聯繫起來的基於細分的關鍵見解。

細分市場揭示了清晰的臨床需求和商業性路徑，這要求研發人員和醫療服務提供者採取個人化的方法。按治療領域分類，市場格局包括化療、聯合治療、CTLA-4、PD-1 和 PD-L1 抑制劑免疫療法以及包括 ALK、EGFR 和 ROS1 抑制劑標靶治療。每個治療領域都有其獨特的療效特徵、安全性考量和監測要求，這些都會影響藥物目錄和處方模式。按癌症類型分類，非小細胞肺癌和小細胞肺癌具有不同的治療模式、顯著不同的分子特徵和治療反應，導致不同的診斷和治療路徑。

從區域戰略觀點，將美洲、歐洲、中東和非洲以及亞太地區在監管差異、診斷系統和醫療保健服務模式方面的細微差別與商業化選擇聯繫起來。

區域趨勢對肺癌治療領域的臨床實踐、監管預期和商業性可行性有顯著影響。在美洲，監管的柔軟性、支付方的競爭力以及先進的診斷基礎設施促進了免疫療法和標靶治療的快速普及。然而，分散的支付方格局要求制定細緻的准入策略並提供可靠的衛生經濟學證據。在該地區的大型腫瘤中心和綜合醫療網路中，從以急性期治療為中心的醫院護理向門診和居家治療的轉變尤為顯著，迫使企業相應地調整分銷和支持服務。

領先的製藥和生物技術公司如何整合其研發管線、診斷技術、生產彈性以及基於價值的契約，以在肺癌治療領域競爭？

主要企業正拋棄單一產品策略，轉型為整合式平台，透過深厚的研發管線、診斷夥伴關係和商業性支持，維持長期競爭力。創新企業優先開發單株抗體和小分子藥物，以滿足不同患者群體的需求，同時投資伴隨診斷，以簡化基於生物標記的處方流程和監管互動。策略聯盟、授權協議和選擇性收購等手段常被用於強化產品組合、加速新型作用機制的開發以及擴大生產能力，尤其是在需要特殊生產的生物製藥領域。

為加強臨床開發、供應鏈韌性、診斷整合和以支付方為中心的證據生成，提出切實可行的建議，以增強競爭優勢。

產業領導企業應採取組合策略，平衡創新、價值鏈韌性和以支付方為中心的證據產生。優先投資伴隨診斷和次世代定序合作，以確保識別出可操作的生物標記，從而最佳化患者選擇並增強報銷談判中的價值提案。同時，應實現採購多元化，並探索策略性區域生產和合作生產協議，以減輕關稅成本波動的影響，並保障臨床試驗藥物的穩定供應。

採用透明嚴謹的調查方法，結合專家的直接訪談、二手文獻的整合以及資料檢驗，以檢驗臨床和營運方面的發現。

本調查方法結合了結構化的初步研究、全面的二次研究和嚴謹的整合，確保了研究結果的穩健性和實用性。初步研究包括對臨床專家、藥物安全監測專家、供應鏈負責人和支付方進行深入訪談，並輔以與顧問小組的討論，以檢驗對新興趨勢的解讀。二次研究涵蓋了監管申報文件、同行評審文獻、臨床試驗註冊信息、衛生當局的公共指南以及企業資訊披露，並對臨床聲明、安全性概況和核准流程進行了交叉檢驗。

總之，綜合分析概述了科學進步、診斷準確性和操作調整必須如何融合，才能將治療可能性轉化為可及和永續的護理。

總而言之，目前肺癌治療的特點是科學快速發展、治療模式不斷演變以及複雜的商業性動態，這些都需要協調一致的策略性應對。免疫療法和標靶治療的進步正在改變治療流程，診斷技術的創新使得患者篩選更加精準。同時，政策變化和貿易趨勢也暴露了供應鏈和定價的脆弱性，因此需要採取積極主動的風險緩解措施。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：肺癌治療市場依治療分類

  • 化療
  • 聯合治療
  • 免疫療法
    • CTLA-4抑制劑
    • PD-1抑制劑
    • PD-L1抑制劑
  • 分子標靶治療
    • ALK抑制劑
    • EGFR抑制劑
    • ROS1抑制劑

第9章 按癌症類型分類的肺癌治療市場

  • 非小細胞肺癌
  • 小細胞肺癌

第10章：以分子類型分類的肺癌治療藥物市場

  • 單株抗體
  • 小分子藥物

第11章 肺癌治療藥物市場：依給藥途徑分類

  • 口服
  • 腸外

第12章 肺癌治療藥物市場：依最終用戶分類

  • 居家醫療
  • 醫院
  • 專科診所

第13章 肺癌治療藥物市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第14章 肺癌治療藥物市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 肺癌治療藥物市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 肺癌治療藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國肺癌治療市場

第18章：中國肺癌治療藥物市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene, Ltd.
  • Blueprint Medicines Corporation
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • Genentech, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Janssen Biotech, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mirati Therapeutics, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-434CCDA05288

The Lung Cancer Drugs Market was valued at USD 29.53 billion in 2025 and is projected to grow to USD 32.07 billion in 2026, with a CAGR of 9.31%, reaching USD 55.07 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 29.53 billion
Estimated Year [2026] USD 32.07 billion
Forecast Year [2032] USD 55.07 billion
CAGR (%) 9.31%

An authoritative introduction to how molecular science, immuno-oncology advances and care delivery changes are reshaping lung cancer treatment decisions and priorities

The lung cancer therapeutic landscape is undergoing a dramatic redefinition driven by molecular science, evolving clinical paradigms, and shifting care delivery models. Recent years have seen a transition from one-size-fits-all cytotoxic approaches toward therapies that exploit tumor biology, immune modulation, and precision targeting. Against this backdrop, clinicians, payers, and developers are confronting new choices about sequencing, combination regimens, and patient selection that hinge on diagnostic sophistication and biomarker-driven enrollment.

Consequently, stakeholders must reconcile accelerating scientific progress with practical constraints in access, manufacturing complexity, and regulatory navigation. The interplay between monoclonal antibodies and small molecule drugs, the ascendancy of systemic immunotherapies alongside targeted inhibitors, and the growing role of oral agents in outpatient care are reshaping treatment algorithms. As healthcare systems adapt, the emphasis shifts toward multidisciplinary coordination, real-world evidence generation, and scalable delivery pathways that preserve safety while optimizing outcomes.

This introduction sets the stage for a deeper examination of transformative shifts, policy and tariff implications, segmentation-driven insights, regional dynamics, competitive behaviors, and pragmatic recommendations that collectively inform strategic planning across the lung cancer therapeutics ecosystem.

How immuno-oncology, precision targeting, outpatient delivery trends and evolving diagnostics are collectively transforming clinical pathways and commercial strategies in oncology

Scientific breakthroughs have precipitated transformative shifts in how lung cancer is diagnosed, treated, and managed across care settings. Immunotherapy agents that target CTLA-4, PD-1, and PD-L1 pathways have moved from niche indications to foundational therapies for many patients, and targeted therapies against ALK, EGFR, and ROS1 alterations routinely define first-line strategies for molecularly selected populations. Simultaneously, combination therapy paradigms that pair immunomodulators with chemotherapy or targeted agents are redefining response expectations and toxicity management.

These therapeutic advances coincide with operational shifts: more care is delivered outside the inpatient setting via oral and parenteral regimens tailored to outpatient and homecare administration, while digital health and remote monitoring tools support adherence and adverse event surveillance. Diagnostic capabilities have expanded with next-generation sequencing and liquid biopsy techniques enabling earlier and more precise patient stratification, which in turn elevates the importance of integrated diagnostic-commercial strategies. Regulatory frameworks are adapting to accelerated approvals, real-world evidence requirements, and greater scrutiny of safety signals, creating both opportunities and complexities for developers and providers.

Taken together, these developments demand that stakeholders rethink clinical pathways, supply chain resilience, and stakeholder engagement models to capitalize on therapeutic potential while safeguarding patient access and system sustainability.

The cumulative impact of recent United States trade tariffs on cross-border supply chains, clinical logistics, pricing pressure and strategic manufacturing choices in oncology

The introduction of cumulative tariffs implemented in the United States in 2025 has created a ripple effect across global supply chains, procurement strategies, and pricing arrangements for lung cancer therapeutics. Manufacturers reliant on cross-border supply of active pharmaceutical ingredients, biologic components, or finished goods have faced elevated landed costs that necessitate renegotiation of supplier contracts, regionalized sourcing, or reallocation of production capacity. Consequently, procurement teams and contract manufacturers have had to revisit supplier diversification and inventory strategies to mitigate disruptions.

Clinical trial conduct has also been influenced as sites and sponsors reassess logistics for investigational product distribution, particularly for parenteral biologics that depend on cold-chain integrity. Payers and hospital systems, grappling with margin pressures, have intensified scrutiny of cost-effectiveness and utilization management mechanisms, prompting manufacturers to accelerate value-based contracting approaches and to prepare more robust outcomes data to support reimbursement discussions. In addition, tariffs have encouraged some organizations to invest in domestic manufacturing capabilities or to explore strategic partnerships to insulate supply continuity.

Although tariffs have increased friction, they have also catalyzed adaptive strategies that emphasize regional resilience, regulatory harmonization efforts, and commercial models centered on demonstrable patient benefit. Stakeholders who prioritize supply chain transparency, flexible production, and collaborative contracting are more likely to navigate the evolving trade landscape successfully.

Critical segmentation-driven insights that connect therapeutic classes, cancer types, molecule categories, administration routes and distribution pathways to commercial and clinical strategy

Segmentation illuminates distinct clinical needs and commercial pathways that demand tailored approaches from developers and providers. Based on therapeutic class, the landscape includes chemotherapy alongside combination therapy, immunotherapy with CTLA-4, PD-1, and PD-L1 inhibitors, and targeted therapy encompassing ALK, EGFR, and ROS1 inhibitors; each class carries unique efficacy profiles, safety considerations, and monitoring requirements that influence formulary and prescribing patterns. Based on cancer type, treatment paradigms differ between Non Small Cell Lung Cancer and Small Cell Lung Cancer, where molecular profiling and therapeutic responsiveness vary significantly and drive different diagnostic and care pathways.

Based on molecule type, monoclonal antibodies and small molecule drugs present divergent manufacturing, storage, and administration challenges that affect distribution channels and payer negotiations. Based on route of administration, oral and parenteral therapies require distinct adherence supports and infrastructure, with oral agents often enabling home-based care while parenteral regimens remain tethered to clinic and hospital infusion resources. Based on end user, treatment delivery spans homecare settings, hospitals, and specialty clinics, each imposing different operational workflows, reimbursement codes, and staffing profiles that must be addressed in go-to-market plans.

Finally, based on distribution channel, hospital pharmacy, online pharmacy, and retail pharmacy pathways each shape access, patient convenience, and cost structures. Integrating these segmentation lenses provides a granular perspective on patient journeys, commercial levers, and value communication that can be operationalized across development, market access, and field engagement activities.

Regional strategic perspectives that link regulatory nuance, diagnostic readiness and care delivery patterns across the Americas, Europe Middle East & Africa and Asia-Pacific to commercialization choices

Regional dynamics materially influence clinical practice, regulatory expectations, and commercial viability across the lung cancer therapeutic space. In the Americas, regulatory agility, payer competitiveness, and advanced diagnostic infrastructure support rapid adoption of immunotherapies and targeted agents, while fragmented payer landscapes require nuanced access strategies and robust health economic evidence. Transitioning from acute hospital-centered care to outpatient and home-based administration is especially evident in large oncology centers and integrated delivery networks across this region, prompting firms to calibrate distribution and support services accordingly.

In Europe, the Middle East & Africa, heterogeneous reimbursement models, variable diagnostic capacity, and distinct regulatory pathways shape adoption timelines. Stakeholders in this region contend with differential access to next-generation sequencing and biologic therapies, driving the need for tiered launch strategies and partnerships with regional diagnostic and clinical networks. Meanwhile, in Asia-Pacific, rapid investment in diagnostic capacity, growth of domestic manufacturing, and strong government interest in expanding cancer care access are creating fertile conditions for both global and local players to pursue innovative collaborations. Across regions, localized pricing pressures and supply chain considerations necessitate adaptive commercial approaches that reflect regional infrastructure, regulatory nuance, and payer priorities.

Ultimately, regional insight should inform prioritization of clinical development, market entry sequencing, and partnership models so that resources align with patient needs and systemic capabilities.

How leading pharmaceutical and biotechnology companies are integrating pipelines, diagnostics, manufacturing resilience and value-based contracting to compete in lung cancer therapeutics

Leading companies are evolving beyond single-product strategies toward integrated platforms that combine pipeline depth, diagnostic partnerships, and commercial support to sustain long-term competitiveness. Innovative firms are prioritizing development of both monoclonal antibodies and small molecule agents to address complementary patient populations, while investing in companion diagnostics to secure biomarker-driven prescribing and to streamline regulatory interactions. Strategic alliances, licensing agreements, and selective acquisitions are frequently used to bolster portfolios, accelerate access to novel mechanisms of action, and expand manufacturing capabilities, particularly for biologics that require specialized production.

Operationally, companies are building capabilities in cold-chain logistics, patient support programs, and digital therapeutics that enhance adherence and real-world outcomes reporting. They are also negotiating outcome-based contracts with payers and health systems, placing emphasis on longitudinal evidence generation and registries to demonstrate value. At the same time, resource allocation increasingly favors therapies with clear biomarker-driven patient selection, improved tolerability, or significant quality-of-life benefits, reflecting payer expectations and clinical demand.

As competition intensifies, corporate differentiation will derive from the ability to integrate clinical science with pragmatic commercialization, manufacturing resilience, and compelling evidence of patient-centered benefit.

Practical and actionable recommendations that align clinical development, supply chain resilience, diagnostics integration and payer-focused evidence generation to strengthen competitive positioning

Industry leaders should adopt a portfolio approach that balances innovation with supply chain resilience and payer-aligned evidence generation. Prioritize investment in companion diagnostics and next-generation sequencing partnerships to ensure actionable biomarker identification, which in turn optimizes patient selection and strengthens value propositions during reimbursement negotiations. Simultaneously, diversify sourcing and consider strategic regional manufacturing or co-manufacturing agreements to reduce exposure to tariff-driven cost volatility and to support reliable clinical trial supply.

Operationally, expand capabilities for outpatient and home-based administration through patient support programs, telehealth integration, and adherence monitoring solutions that reduce healthcare system burden and improve therapeutic continuity. Strengthen commercial arguments by collecting prospective real-world evidence and constructing outcomes-based contracting frameworks that align payment with measurable clinical benefit. Finally, pursue collaborative research with academic centers and health systems to design pragmatic clinical studies that address unmet clinical questions, safety in diverse populations, and comparative effectiveness, thereby enhancing dialogue with regulators and payers about meaningful endpoints.

A transparent and rigorous research methodology integrating primary expert interviews, secondary literature synthesis and data triangulation to validate clinical and operational insights

The research methodology combines structured primary research, comprehensive secondary review, and rigorous synthesis to ensure findings are robust and actionable. Primary research included in-depth interviews with clinical specialists, pharmacovigilance experts, supply-chain leaders, and payers, complemented by advisory-panel discussions to validate interpretation of emergent trends. Secondary research encompassed regulatory filings, peer-reviewed literature, clinical-trial registries, published guidance from health authorities, and company disclosures to cross-check clinical claims, safety profiles, and approval pathways.

Data integration relied on triangulation to reconcile disparate sources and to surface consistent signals about treatment adoption, operational challenges, and strategic behaviors. Where appropriate, sensitivity analyses were performed to test assumptions and to understand the implications of policy changes, including tariff effects on supply and distribution. Limitations of the approach are acknowledged: real-world practice can evolve rapidly, and emerging clinical trial data may alter therapeutic positioning. Therefore, the methodology emphasizes transparency in data sources, stakeholder validation, and continual monitoring to maintain relevance as the landscape evolves.

A concluding synthesis outlining how scientific progress, diagnostic precision and operational adaptations must coalesce to convert therapeutic promise into accessible and sustainable care

In summary, the lung cancer therapeutic landscape is characterized by rapid scientific progress, shifting delivery models, and complex commercial dynamics that require coordinated strategic responses. Advances in immunotherapy and targeted agents are altering treatment algorithms while diagnostic innovation enables more granular patient selection. At the same time, policy shifts and trade dynamics have exposed vulnerabilities in supply chains and pricing that necessitate proactive mitigation measures.

Stakeholders who align biomarker-driven development with pragmatic distribution strategies, invest in domestic or regional manufacturing resilience, and embrace outcomes-based engagement models with payers will be better positioned to deliver sustained patient benefit. Cross-functional collaboration among developers, diagnostics providers, providers, and payers is essential to translate therapeutic potential into accessible, safe, and economically sustainable care. Continued surveillance of clinical trial results, regulatory decisions, and regional access dynamics will be critical to iteratively refine strategy and to ensure that innovations reach the patients who can benefit most.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Lung Cancer Drugs Market, by Therapeutic Class

  • 8.1. Chemotherapy
  • 8.2. Combination Therapy
  • 8.3. Immunotherapy
    • 8.3.1. Ctla-4 Inhibitors
    • 8.3.2. Pd-1 Inhibitors
    • 8.3.3. Pd-L1 Inhibitors
  • 8.4. Targeted Therapy
    • 8.4.1. Alk Inhibitors
    • 8.4.2. EgfR Inhibitors
    • 8.4.3. Ros1 Inhibitors

9. Lung Cancer Drugs Market, by Cancer Type

  • 9.1. Non Small Cell Lung Cancer
  • 9.2. Small Cell Lung Cancer

10. Lung Cancer Drugs Market, by Molecule Type

  • 10.1. Monoclonal Antibodies
  • 10.2. Small Molecule Drugs

11. Lung Cancer Drugs Market, by Route Of Administration

  • 11.1. Oral
  • 11.2. Parenteral

12. Lung Cancer Drugs Market, by End User

  • 12.1. Homecare Settings
  • 12.2. Hospitals
  • 12.3. Specialty Clinics

13. Lung Cancer Drugs Market, by Distribution Channel

  • 13.1. Hospital Pharmacy
  • 13.2. Online Pharmacy
  • 13.3. Retail Pharmacy

14. Lung Cancer Drugs Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Lung Cancer Drugs Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Lung Cancer Drugs Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Lung Cancer Drugs Market

18. China Lung Cancer Drugs Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Amgen Inc.
  • 19.6. AstraZeneca PLC
  • 19.7. Bayer AG
  • 19.8. BeiGene, Ltd.
  • 19.9. Blueprint Medicines Corporation
  • 19.10. Bristol-Myers Squibb Company
  • 19.11. Daiichi Sankyo Company, Limited
  • 19.12. Eli Lilly and Company
  • 19.13. Genentech, Inc.
  • 19.14. Gilead Sciences, Inc.
  • 19.15. GlaxoSmithKline plc
  • 19.16. Janssen Biotech, Inc.
  • 19.17. Johnson & Johnson
  • 19.18. Merck & Co., Inc.
  • 19.19. Mirati Therapeutics, Inc.
  • 19.20. Novartis AG
  • 19.21. Pfizer Inc.
  • 19.22. Roche Holding AG
  • 19.23. Sanofi S.A.
  • 19.24. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL LUNG CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL LUNG CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ALK INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ALK INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ALK INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY EGFR INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY EGFR INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ROS1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ROS1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ROS1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY SMALL CELL LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY SMALL CELL LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. GCC LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GCC LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 161. GCC LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 162. GCC LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 163. GCC LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. GCC LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. GCC LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 166. GCC LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. GCC LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. G7 LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. G7 LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 188. G7 LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 189. G7 LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 190. G7 LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. G7 LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. G7 LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 193. G7 LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. G7 LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. NATO LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. NATO LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 197. NATO LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 198. NATO LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 199. NATO LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. NATO LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. NATO LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 202. NATO LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. NATO LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)